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A variety of human papillomavirus (HPV) types infect the anogenital mucosa, giving rise to
lesions that differ in clinical appearance, histology, and risk of malignant progression. Certain
high-risk types (HPVs 16, 18, 31, 33, 35, and 39) have a strong association with high-grade
epithelial neoplasia and invasive carcinomas of the anogenital tract. Cancer appears to have a
multifactorial etiology, and HPV infection alone is probably insufficient for malignant transfor-
mation. The consistent association between HPV infection and anogenital cancers emphasizes,
however, that the sexually transmitted papillomaviruses may have a necessary role in carcinogen-
esis. Hence, there is a prospect thatvaccination programs mayoneday allow public health control
ofHPV infection, thereby eliminating an important risk factor.
INTRODUCTION
Invasive squamous cell cancer of the uterine cervix is one of the most common
cancers of the female genital tract. Worldwide, cervical cancer is the greatest cancer
killer ofwomen under the age of40 years, and the frequency ofthe disease in younger
women appears to be increasing [1,2,3]. When cervical cancer does occur in this age
group, the tumor tends to be poorly differentiated and has a proclivity to more rapid
systemic spread [3,4]. This process carries an attendant threat ofmoredrastic therapy,
including chemotherapy.
Cervical cancer has long been considered a sexually transmitted disease [5,6].
Epidemiological research has shown that sexual intercourse is pivotal in determining
risk [7,8]. Specific sexual behavioral characteristics, such as early age of coitarche
[9,10] and multiple sexual partners [11], define women at high risk of cervical
neoplasia. Rotkin, in 1967, therefore proposed the concept ofthe male as the vector of
some carcinogenic agent transmitted to the female sexual partner at the time of
intercourse [12], an agent showing a marked affinity for the unstable squamous
metaplastic cells ofthe immature cervical transformation zone.
Vulvar cancer remains uncommon. Within the last forty years, however, the
incidence of vulvar intraepithelial neoplasia grade 3 (VIN 3; severe dysplasia/
carcinoma in situ) has increased, while the modal age at diagnosis has fallen by two
decades, to 30 years ofage [18]. Women with vulvar neoplasia show an increased risk
ofcervical neoplasia, suggesting a field effect by a common causative agent [19].
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Still less is known about the etiology of the less common squamous genital cancers,
particularly vulvar and penile carcinoma. Although penile cancer is much less
common, the incidence ofcervical and penile cancer actually correlates in a number of
countries [13]. A man with either penile cancer or carcinoma in situ ofthepenis places
his partner at increased risk ofcervical neoplasia [14,15,16]. Conversely, 5-10 percent
of male partners of women with cervical neoplasia will have penile intraepithelial
neoplasia (severe dysplasia/carcinoma in situ) [17].
The association between cervical, vulvar, and penile neoplasia implies transmission
ofan infectious oncogenic agent. Herpes simplex virus was previously suspected as this
infectious carcinogen. Two decades of research, however, have failed to produce
evidence that convincingly relates herpes viruses to cervical cancer. The candidacy of
the papillomaviruses was suggested over ten years ago by Zur Hausen [20]. Since
papillomaviruses could not be propagated in cell culture, however, virologists of the
day had no effective tools with which to study this hypothesis. Advances have only
occurred since the advent of molecular biology. This exciting new technology has
helped to unravel the plurality ofpapillomaviruses, their prevalence in various tumors,
and aspects oftheir biology. Such data have strengthened speculation regarding a role
of papillomaviruses in the etiology ofgenital cancer.
The human papillomaviruses (HPVs) are site-specific DNA viruses that produce
characteristic proliferations on epidermal and mucosal surfaces. Papillomaviral infec-
tion ofthe genital tract is common among sexually active women [21]. Since clinically
detectable condylomata acuminata are seldom seen on the cervix, it was traditionally
believed that HPV infections were limited to theproduction ofpapillomas affecting the
lower vagina, vulva, and anus. In the past, cervical HPV infections were overlooked
because the lesions are most frequently macroscopically flat and entirely invisible
without the aid ofacetic acid [22]. When seen at colposcopy, thesechanges were either
dismissed as physiological variations or misinterpreted as mild dysplasia. In the
mid-1970s, however, it was recognized that 1-2 percent ofall smears from women with
a clinically normal cervix displayed cytologic signs of HPV infection [23,24,25] and
that many mild dysplasias showed only viral proliferation, without any real evidence of
neoplastic transformation [22,24]. That is to say, it was now apparent that the most
common manifestation ofsexually transmitted HPV infection was a non-papilliferous
hyperplasia of the metaplastic epithelium of the transformation zone [26]. The only
major difference between clinically overt and subclinical condylomas is their macro-
scopic appearance. Both variants show essentially identical histology, both forms are
infectious, and both lesions denote a risk ofneoplastic transformation.
At first, this new insight led to the widespread assumption that the task for the
future was to define morphologic criteria by which benign papillomaviral infections
could be differentiated from real pre-malignancies. There never was, in fact, any
experimental basis for such a belief. Conversely, there has been a rapid accumulation
ofhistologic, serologic, and virologic evidence linking both minor and major grades of
cervical neoplasia with papillomaviral infection [27]. As an additional complexity, the
common genital varieties of papillomavirus (types 6 and I1) were mainly associated
with eithervenereal warts or minorgrades ofdysplasia, whereas high-risk HPVs (types
16, 18, 31, 33, 35, and 39) have been found mainly in high-grade pre-malignancies or
invasive cancers [28]. While these data suggest that only a fraction of cervical HPV
infections are potentially malignant, it must be remembered that there is substantial
morphologicoverlap between lesions caused by the differentviral types. In essence, the
308GENITAL HPV INFECTION
triage of the abnormal Papanicolaou smear amounts to the differentiation between
benign warty proliferation, minor-grade dysplasia, and full-thickness intraepithelial
neoplasia [29]. Hence, a clear understanding of the biology, morphologic expression,
and natural history ofpapillomaviral infection is essential to the rational management
ofpatients with lower genital tract neoplasia.
BASIC VIROLOGY OF THE PAPILLOMAVIRUSES
Taxonomy
Papillomaviruses are small, double-stranded DNA viruses. Because of superficial
similarities in electron microscopic appearance and biologic properties, papillomavi-
ruses were originally classified within the same family as polyomaviruses, this group
being termed papovaviruses [30]; however, papillomaviruses (genus A) have a larger
chromosome (7,900 versus 5,200 base pairs), a larger virion capsid (55 versus 44 ,um),
and a completely different genomic organization [31]. Hence, it would be best to
regard papillomaviruses as a distinct and unique family.
Polyomaviruses (genus B) are readily passaged in tissueculture, transform cell lines
in vitro and are oncogenic in animals ofother species; genus B viruses do not, however,
usually cause widespread disease in their natural hosts. The main scientific importance
of the polyomavirus subgroup has been as laboratory models of viral oncogenesis. In
contrast, papillomaviruses cannot be propagated in tissue culture and do not generally
induce infection in other species. Rather, the papillomaviruses are host- and site-
specific viruses that cause benign skin tumors (warts) in their natural hosts, some of
which tumors evolve into squamous cancer.
In reality, papillomaviruses represent a divergent group of evolutionarily related
viruses which manifest qualitatively similar biological characteristics; however, indi-
vidual papillomaviruses show enormous differences in species specificity, site of
predilection, and degree ofoncogenicity. All papillomaviruses exhibit a similar pattern
ofgenetic organization, in that sequencing ofthe different types has shown presevation
ofbroadly equivalent areas ofprotein coding potential (known as open reading frames
or "ORFs"); however, the actual nucleotide sequences within these ORFs are widely
disparate [31]. Hence, papillomaviruses are named according to species and subclas-
sified into types according to nucleotide sequence. Within the same species, any new
isolate which exhibits less than 50 percent homology (by solution hybridization) with
existing members is designated as a new type and numbered in order of discovery.
Human papillomaviruses (HPV) comprise the largest group, with more than 55 known
types. Other members of scientific importance include the cottontail rabbit, bovine,
canine, ovine, equine, elk, and mastomys papillomaviridae.
Virion Structure
Papillomavirus particles, whether isolated from infected rabbits, cattle, or humans,
are remarkably similar in overall appearance. Virions consist of a central core ofviral
DNA, enclosed within an outer capsid ofviral protein. The viral capsid is composed of
72 subunits (capsomeres), which are arranged in symmetrical, 20-sided (icosahedral)
pattern that gives the individual virion an almost spherical shape on electron
microscopy (Fig. 1). The virion does not have an outer membrane such as is found in
some other viruses (for example, human immunodeficiency virus). This fact may
account for the low antigenicity ofpapillomavirus infections (Figs. 2 and 3).
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FIG. 1. Electron micro-
graph of formed virions in a
condyloma acuminatum.
The icosahedral shape of the
viral capsid is apparent.
Biochemical analysis of the viral capsid has revealed two different families of
structural protein: a major protein (molecular weight, 54,000 daltons) and a minor
protein (molecular weight, 76,000 daltons) [32]. Denatured major capsid proteins of
all animal and human papillomavirus are highly cross-reactive and serve as genus-
specific antisera. In contrast, the minor capsid proteins appear to be highly type-
specific and might one day provide a suitable target for immunocytochemical typing of
biopsies.
DNA Organization
All papillomavirus chromosomes are covalently closed, circular, double-stranded
DNA molecules with a molecular length of about 7,900 base pairs and a molecular
weight ofabout 5.2 x 106 daltons (about halfa million times smaller than the genome
of a human cell). In contrast to mammalian chromosomes, all of the viral genetic
information is contained onjust one ofthe paired DNA strands.
Whether isolated from disrupted virions or extracted from transformed cells, the
viral DNA is combined with histones (derived from the cellular pool of the natural
host), to form a small chromosome [33]. Thus, viral DNA constitutes only 12 percent
of the virion by weight. When the nuclear proteins are stripped away, the viral DNA
assumes a super-coiled shape (form I). Super-coiling is visible on electron microscopy
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FIG. 2. A clinical condy-
loma acuminatum on the
- cervix of an 18-year-old wo-
man. Such a lesion was pre-
viously considered very rare.
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FIG 3. A. A Papani-
colaou smear showing cy-
Aj1 i _;7 .topathic effects of HPV
NJ.-"'?i Pi p infection, specifically koilo-
cytoticatypia (K) character-
ized by nuclear atypia and
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grade lesion.
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Viral Genetic Function
As previously mentioned, alignment ofsequenced papillomaviruses' DNAs revealed
a highly conserved pattern ofprotein coding potential, these areas with protein coding
potential being termed open readingframes (ORFs). In essence, each of these ORFs
represents a viral gene, which will determine such characteristics as host range, tissue
tropism, and the clinicopathologic consequences ofinfection.
Studies ofthe non-productive interaction ofBPVs with mouse fibroblasts has shown
that theviral genome can be subdivided into three functional portions. While it has not
been experimentally demonstrated that the same relationship holds for HPV infection
of epithelial cells, it is still valuable to examine human disease in relationship to this
model.
The upstream regulatory region (URR) The upstream regulatory region is a
non-coding segment representing about 15 percent of the viral genome. This region
contains theorigin ofDNA replication, several promoters (sequences needed to initiate
viral mRNA synthesis), and several enhancers (sequences that increase the rate of
RNA transcription) [34,35,36]. From the functional viewpoint, enhancers fall into two
groups: those which bind to the viral genome (thereby regulating the production of
othervirus-encoded proteins) and those which bind to host receptors (thereby inducing
a conducive host cellular milieu).
The URR is the genetic interval most likely to be divergent among viral types, and
someofthesedifferences have been correlated with changes in virulence and oncogenic
potential [31]. Moreover, these differences provide much of the basis for the
type-specific diagnostic probes [37].
The E (early) region The E region is a long segment, representing about 45
percent oftheviral genome. This region contains at least seven ORFs, all ofwhich code
for proteins that either maintain cell transformation or control viral DNA replication.
Each ORF was named according to relative size. Hence, the number assigned to a
particular ORF bears no relationship to its actual location within the E region of the
viral genome.
Functions ofindividual ORFs, are as follows (reviewed in [311):
El ORF controls the episomal replication of viral DNA [38]. This viral gene
appears to have two parts: a positive control (the El-C domain) and a negative control
(the El-M domain). Experiments in cell cultures suggest that, shortly after transfec-
tion, viral copy numbers rise to about 150-200 (due to El-C "up" regulation) and
thereafter drop to about 20-50 copies per cell (due to El-M "down" regulation).
Preservation of an intact El ORF, appropriately located downstream of the URR,
appears to prevent integration of the viral genome into the host cell chromosome (see
below).
E7 ORF also plays a role in regulating viral copy number during episomal DNA
replication [39]. It is not, however, presently clear whether E7 proteins are involved in
maintaining "steady-state" levels of HPV DNA in latently infected epithelial cells or
in promoting the high copy numbers seen in vegetative viral infections.
A 20,000-dalton E7 protein has been found in human cervical cancers [40],
indicating that this viral gene may also play a role in malignant transformation.
E2 ORF produces a pair of competing proteins that bind to the upstream
regulatory region and function either to promote or to inhibit viral transcription. The
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E2 ORF may have an important role in producing or maintaining "benign" cellular
transformations.
E5 ORFalso plays a role in cell transformation, apparently by producing a small
(7,000-dalton) protein which binds to cytoplasmic membranes. Deletion of the E5
protein appears to impair episomal DNA replication, perhaps favoring integration of
viral DNA into the cellular chromosome [31].
E6 ORF produces an 18,000-dalton protein that is involved in "malignant"
cellular transformation and in the alteration of growth properties within cell culture.
The E6 region has been conserved and is transcribed in all of the HPV-containing
human tumor biopsies and cervical cancer-derived cell lines analyzed to date [31].
E4 ORF produces several proteins that are found in relative abundance as
parabasal cells differentiate into mature keratinocytes, and it is thought that messages
from this region initiate the onset of koilocytotic changes. Not surprisingly, the E4
ORF is usually deleted from carcinomas.
The L (late) region The L region comprises about 40 percent oftheviral genome
and contains two ORFs that are essential to vegetative viral replication:
LI ORFencodes the major capsid protein (molecular weight 54,000 daltons). The
LI gene product is highly conserved among most animal and human papillomaviruses.
Accordingly, antisera directed against disrupted, denatured HPV-1 capsid are used as
cross-reactive, group-specific immunocytochemical reagents. Only about 50 percent of
genital condylomas produce detectable LI protein, however, and this percentage
declines with increasing degrees ofneoplasia [41].
L2 ORF encodes the minor capsid protein (molecular weight, 76,000 daltons).
Marked variation has been found among the nucleotide sequences for the L2 ORF.
Hence, L2 proteins might serve as distinguishing targets for immunocytochemical
typing of infected tissues. Within the intact virion capsid, however, type-specific
epitopes of the L2 protein are shielded and probably could not form the basis for a
vaccine [32].
DNA Replication
After transport ofviral DNA to the cell nucleus, it apppears that the El-C (positive
regulatory) protein binds to the origin of replication in the URR and initiates
"runaway" replication [31]. Initial copy number may rise as high as 200 per cell but is
thereafter stabilized at about 20-50copies (as a result ofdown regulation by El-M and
E7 modulator functions). To this point, it does not appear that there are any steps in
viral DNA replication which could be targeted for selective blockage. Hence, any drug
which would attack viral DNA replication would probably also disturb host cell
function. The best prospect for a drug to block viral replication would appear to be a
chemical active against the E7, El-M, or El-C viral proteins.
RNA Transcription
RNA transcription mapping is still at a preliminary stage. Current data suggest that
papillomaviruses use complex splicing techniques as a means of specifying messages
from different ORFs. One important difference in the high-risk viruses HPV 16 and 18
(relative to the low-risk viruses HPV 6 and I 1) is the presence ofadditional splice sites
within transcripts spanning the E6 ORF. These additional splice sites lead to a
313REID AND CAMPION
truncated form of the E6 protein, termed E6* [40]. This E6* protein may have
properties important to transformation and carcinogenesis. In addition, a different
species of RNA has been identified in tumor cells, wherein part of the viral message
has been deleted and replaced by a segment ofhost cell RNA. This arrangement might
account for the increased half-life ofviral transcripts in malignant cell lines.
The production of subgenomic RNA probes, small enough to detect messages
encoded by the individual ORFs, has now made it possible to study the tissue
distribution and relative abundance of the signals from the different viral genes [37].
These studies show continued early gene expression from parabasal to superficial
layers. In contrast, messages from the LI and L2 ORFs are mainly confined to the
superficial strata.
CLINICAL GROUPS OF HUMAN PAPILLOMAVIRUSES
From the viewpoint of biologic properties, human papillomaviruses comprise three
clinicopathologic groups: cutaneotropic viruses found in immunologically normal
individuals, cutaneotropic viruses causing epidermodysplasia verruciformis in immu-
nosuppressed patients, and mucosotropic viruses infecting the genital, oral, and
respiratory mucosae.
Cutaneous HPVs in the Immunocompetent Population
Viruses in this group always produce vegetative infections which, by definition, can
never be carcinogenic. Viral type correlates with lesion location, clinical features, and
histologic appearance.
HPV I and 4 are usually found in plantar warts, HPV 1 being preferentially
associated with deep, painful lesions and HPV 4 with more superficial varieties.
HPV2 is found in common warts (verrucaevulgaris) which are ususally acquired
in childhood, causing very keratotic lesions that primarily affect the dorsal skin of the
upper or lower limbs.
HPV3 occurs in flat warts (seen as minimally elevated red patches on the hands
and face).
HPV7 produces common warts in meat and animal handlers.
Such site specificity probably reflects the fact that susceptibility to viral infection
depends upon the types ofkeratin produced during terminal differentiation. Hence, the
relationship between viral type and lesion morphology is quite constant. Nonetheless,
occasional exceptions occur, such as reports ofHPV 1 or 4 in common warts, or HPV 2
in plantar or genital warts.
HPVs Affecting the Anogenital andAerodigestive Mucosae
About a dozen of the known HPV types are mucosotropic, infecting either
anogenital skin or mucous membranes. These viruses are also associated with specific
disease patterns:
HPV6and 11 are primarily responsible for twotypes ofdisease: papillomas ofthe
upper airways and benign exophytic condylomas affecting the external genitalia, lower
third of vagina, and anal canal. Detection of HPV 6 or 11 in minor lesions of the
transformation zone has fostered a mistaken belief that these types account for the
majority of minor cervical atypia. In fact, HPV 6 or 11 probably causes only between
15 and 50 percent of"flat condylomas" or mild dysplasias [42].
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HPV 16 is the viral type detected universally with greatest frequency in
high-grade intraepithelial neoplasia and invasive cancers. Nonetheless, HPV 16 is also
found in 15-40 percent of minor-grade cervical lesions [21,43]. Moreover, in a
high-risk British population, HPV 16 was also found in 40 percent ofsubclinical lesions
on the vulva and penis and in up to 10 percent ofcondylomata acuminata, particularly
recalcitrant lesions.
HPV18 shows a bimodal distribution pattern, being present in about 5 percent of
invasivecervical cancers (especially aggressive adenocarcinomas ofyoung women) and
about 5 percent of minor-grade genital lesions. HPV 18 is, however, significantly
underrepresented in patients with only cervical intraepithelial neoplasia, suggesting
that this virus may produce lesions that progress too rapidly for reliable detection by
mass screening programs.
HPV31, 33, 35 and 39 exhibit intermediate oncogenicity, with a predilection for
the squamous cells of the cervix or vagina. The "thirties" viruses are a little
overrepresented in cervical intraepithelial neoplasia (CIN) (about 30 percent) and
underrepresented in cervical cancer (about 10 percent).
Cutaneous HPVs in Immunosuppressed Individuals
Almost half of the presently known HPV types have been isolated from the skin of
immunosuppressed individuals. The main source of these novel cutaneotropic viruses
has been patients suffering from a rare disease termed epidermodysplasia verruci-
formis (EV). This disease is characterized by multiple flat warts of non-genital skin,
generally affecting patients wtih congenital impairment of their cellular immunity.
Malignant conversion ofthese flat warts occurs in association with infection by specific
"high-risk" HPV types, as discussed below. Similar HPV types have also been isolated
from warts in patients taking immunosuppressive drugs and in skin cancers occurring
in renal allograft recipients. Since it is highly unlikely that these HPV types could
persist in nature if they infected only EV patients and other immunocompromised
individuals, it is reasonable to speculate that latent infection ofnormal individuals may
serve as the reservoir for these rare viruses.
MALIGNANT CONVERSION OF PAPILLOMAVIRUS INFECTIONS
Some papillomaviruses induce tumors which may progress to carcinoma. Skin warts
of cottontail rabbits were first shown to convert into carcinomas in 25 percent of
infected animals, long-persisting papillomas becoming malignant after about one year
[42]. Chemical carcinogens (such as tar) greatly accelerated the conversion rate [43].
This rabbit system reveals many basiccharacteristics ofpapillomaviral oncogenesis. In
most experimental models, these viruses were weakly oncogenic alone; effective
carcinogenesis usually depended upon exposure to other physical or chemical carcino-
gens (such as ultraviolet light, X-rays, or special dietary components).
The rare hereditary skin disorder, epidermodysplasia verruciformis, provides an
excellent human model for study of malignant warts [46,47,8]. Unlike other warts,
these flat lesions do not regress. Rather, lesions persist for life, spreading over the
entire body. Experience has shown that 25-33 percent of affected individuals will
develop skin cancer, usually within sunlight-exposed areas. Lag time between the
appearance of flat warts and progression to squamous carcinoma averages about 25
years.
Although more than 15 different HPV types have been isolated from skin lesions in
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the patients, HPVs 5 and 8 are detected in 90 percent of malignancies [47,48]. The
preferential location of skin cancers within sunlight-exposed areas is another example
ofsynergism between papillomavirus infection and extrinsic factors.
Infants born to women with HPV 6- or 1 -induced genital condylomata acuminata
are at a small but definite risk ofdeveloping laryngeal papillomatosis [49,50]. Because
ofthe often incurable nature oflaryngeal papillomatosis, this disease was once treated
by radiation therapy. Malignant conversion of the benign tumors induced by "low-
risk" genital HPV types has been reported in such patients [49]. This process is a
further example of synergism between an HPV infection and a cofactor in human
carcinogenesis.
HPV AND GENITAL NEOPLASIA
HPV Types in Genital Tumors
The site-specific preference of the individual HPVs sometimes reflects a degree of
similarity in viral genomic organization. For example, HPVs 6 and 11 have identical
tropism and pathogenic properties. Although these viruses are classified as different
types (because they show only 25 percent cross-reactivity when analyzed by reassocia-
tion kinetics in liquid phase), actual sequence analysis has demonstrated almost 90
percent homology ofnucleotide base pairs [50,51]. Likewise, HPVs 16 and 31 are also
closely related at the nucleotide level [52]. HPV 33 is distantly related to HPV 16, but
this fact poses no problem for differentiation. HPV 18 and HPV 35 have no close
relatives among other known HPVs. Nonetheless, viruses originally isolated from skin
warts are occasionally found in genital tumors. HPVs 1 and 2 have been detected in
condylomata acuminata [53]. HPV 10 has been reported in both condylomata
acuminata and cervical cancer tissue [54]. HPV 34 was originally cloned from Bowen's
disease of the skin but has also been reported in an isolated case ofvulvar intraepithe-
lial neoplasia grade 3 [55].
Morphology ofGenital HPV-Induced Disease
Condylomata Acuminata Exophytic condylomas usually present as soft, pink or
whitish, vascular, sessile tumors with multiple, fine, finger-like projections. They occur
primarily in moist areas, especially those exposed to coital friction. Thus, the most
common sites are the posterior part of the introitus, the adjacent labia minora,
throughout thevestibule, and on the perianal or anal skin. Lesscommonly, condylomas
occur in the clitoral region (even under the clitoral hood) and may extend on to the
mons pubis. In the non-mucosal areas, the condylomas may be more keratotic and less
papilliferous, similar in appearance to the typical hand warts (verruca vulgarae).
Condylomata acuminata now represents one ofthe most common sexually transmit-
ted diseases. The viral etiology has been clearly proven [56]. Over 60 percent ofsexual
partners ofinfected individuals develop lesions after an incubation period offour to six
weeks. The vast majority ofexophytic condylomata acuminata are induced by HPV 6
(65 percent) or HPV 11(20 percent). Mixed infections involving more than onegenital
HPV type are not uncommon. Importantly, HPV 16 is detected in up to 10 percent of
these common, benign genital proliferations [57].
The reported incidence of vulvar condylomata acuminata has greatly increased
throughout the Occidental world over the past 20 years. In the United Kingdom, the
reported incidence has risen 10 percent per year, and there has been a 460 percent
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FIG. 4. A colpophoto-
graph of extensive cervical
HPV infection in a 23-year-
old woman who was cur-
rently 28 weeks pregnant.
HPV II DNA was extracted
from a cervical smear from
the lesion. This finding has
implications for delivery to
minimize the risk of neo-
natal transfer and laryngeal
papillomatosis in the new-
born.
increase in the United States over the last 15 years [57]. Age incidence peaks between
16 to 25 years, as does that ofother sexually transmitted diseases.
Exophytic condyloma acuminatum of the cervix was once considered a very rare
tumor; however, careful examination has revealed exophytic papillomas in up to 15
percent of women with vulvar lesions [58]. Women with vulvar condylomata acumi-
nata are at a greatly increased risk of having associated cervical intraepithelial
neoplasia (CIN) [59]. Cervical cytology and colposcopy should be part ofthe work-up
of women presenting with condylomata acuminata. Similarly, women who are the
sexual contacts of men with penile condylomata acuminata are at greatly increased
risk of cervical neoplasia and should also be offered cervical cytology and colposcopy
[60].
Progression of condylomata acuminata to cancer is well documented in both sexes;
however, the relative risk is very low [20]. Rarely, large "condylomas" may show
excessive growth with associated local invasion. Such slowly spreading, genital masses
are termed giant condylomas of Buschke-Lowenstein or verrucous carcinomas. These
lesions, which are usually induced by either HPV 6 or 11, represent indolent
malignancies that rarely metastasize [58].
HPV-Induced Papular Lesions HPV infection of the vulvar skin can also
produce small (3 to 7 mm), smooth, flat papules. Lesions may be pigmented or
non-pigmented, or, in dark-skinned women, associated with depigmentation. Papules
frequently occur in association with condylomata acuminata but may occur in the
absence of other HPV-induced clinically apparent disease. Lesions frequently are
multiple, sometimes coalescing to produce a larger area ofdisease (Fig. 4).
The histology ofthese papular lesions is quite variable, ranging from the features of
benign HPV infection to significant epithelial dysplasia. Up to 90 percent of vulvar
papules contain HPV 16 DNA. Hence, these inconspicuous lesions may represent an
important male and female reservoir for oncogenic HPV types [57].
Subclinical Papillomavirus Infections It is now generally accepted that most
genital HPV infection is subclinical, becoming visible only after the application of
acetic acid. Cytologic and histologic features of overt and subclinical infections are
essentially the same, koilocytotic atypia and dyskeratosis being prominent microscopic
features ofboth forms ofsexually transmitted HPV infection.
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FIG. 5. A colpophoto-
graph of a major-grade
lesion with a well-defined
regular border and widely
spaced punctation and mo-
saicism. Histology revealed
CIN III, and HPV 16 DNA
was extracted.
Colposcopic differentiation between subclinical papillomaviral infection (SPI) and
high-grade CIN is relatively difficult. Although this diagnosis will ultimately be made
by histology, a colposcopic impression is important in order to direct biopsy to areas of
most significant disease. On the cervix, subclinical HPV infections are characterized
colposcopically byeither indistinctaceto-whitening ora shiny, snow-white lesion, by an
irregular outline with jagged, angular, or feathered margins, and by the presence of
satellite lesions extending beyond the transformation zone. Capillary patterns may be
pronounced and are often confused with the mosaicism and punctation characteristic
ofCIN 2-3; however, the vascular pattern ofSPI is composed ofuniform, fine-caliber
vessels, loosely and randomly arranged, often as a horizontal mesh reminiscent of
bizarre spider webs. Non-dilated capillary loops may also run vertically toward the
surface, maintaining a uniform vessel caliber throughout their course. Staining with
quarter-strength Lugol's iodine is a further aid to colposcopic diagnosis. Positive or
partial staining denotes glycogenation, in contrast to the negative staining shown by
areas ofsignificantly transformed CIN.
Cervical SPI represents a heterogenous group of lesions. The majority are due to
infection by low-risk or unspecific HPV types, for example, HPV types 6 or 11.
Current evidence suggests that, despite their role in causing abnormal Papanicolaou
smears, such lesions are not common antecedents ofcervical cancer.
In contrast, the 15-50 percent ofsubclinical cervical lesions induced by HPV 16, 18,
31, 33, 35, or 39 do indeed represent the earliest point in the pre-cancerous spectrum
[43,57]. While some workers have suggested that minor-grade lesions containing
high-risk HPVs are distinguishable from "non-precursors" by the presence ofatypical
mitotic figures [61], this finding has not been our experience [42,57,62,63].
Women with a history of koilocytotic atypia on a cervical smear have an increased
risk of CIN 3 and invasive cancer [64]. Such retrospective studies do not, however,
provide conclusive evidence of the progressive potential of SPI. If colposcopy is
scheduled, over 30 percent ofwomen whose smear showed only koilocytotic atypia will
have cervical neoplasia confirmed at direct biopsy.
Evans and Monaghan demonstrated that 16 percentofhistologically proved cervical
SPI progressed to CIN 2-3, including one microinvasive carcinoma within a 12-month
period [65]. This progressive potential ofmild cervical atypia was also documented by
Campion and colleagues in a recent prospective study [43]. Of women with cytologic
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and colposcopic evidence of mild cervical atypia, 26 percent progressed to histologi-
cally proved CIN 3 within a two-yearperiod. In 85 percent ofthe women whosedisease
progressed rapidly, a cervical smear was positive for HPV 16 on filter hybridization at
theoutset ofprospective follow-up. Moreover, the spontaneous regression ratewasvery
low (11 percent). Those women who did regress remained at high risk of future
recurrence of their cervical disease. These results were very similar to the earlier
prospective study of Richart and Barron [66], but the transit time to CIN 3 for this
modern group ofwomen was shorter. The progressive potential ofCIN 3 is established
[67]. This fact may reflect the increased incidence of CIN 3 and invasive cancer in
young women in the United Kingdom and elsewhere in the Western world over the past
decade.
Unless HPV typing becomes a clinical routine, it is best to regard cervical SPI and
CIN 1 as biological equivalents; that is to say, the earliest stages in the pre-malignant
spectrum representing a heterogenous group of lesions with differing natural history.
Prospective follow-up, in summary, suggests about one-third of minor-grade lesions
will progress to CIN 3, about one-third will regress, and about one-third will persist
unchanged for years. Hence, a policy of empiric transformation zone ablation still
represents the safest and most cost-effective management for such minor-grade atypia.
Further research is required to determine whether such minor-grade lesions can be
safely triaged for treatment or follow-up according to HPV type.
Subclinical HPV infection is also common in the vagina and vulva. Vaginal lesions
present in one of these forms: (1) elongated vaginal papillae, (2) flat aceto-white
epithelium, and (3) reverse punctation.
Vulvar SPI can be either micropapillary or completely flat and therefore invisible
without the aid of acetic acid soaking. The subclinical vulvar lesions are sometimes
symptomatic, producing chronic pruritus, burning, or post-coital pain.
Penile Skin and Anal Region The concept of cervical neoplasia as a sexually
transmitted disease has resulted in contact tracing of male partners [68,69]. Such
studies have shown that 10-15 percent of the current male consorts of women with
CIN will have overt penile condylomas; another 50 percent will have subclinical penile
lesions which can only be seen after the male genitalia have first been soaked with
white vinegar. It is especially noteworthy that 5-10 percent ofmale partners ofwomen
with CIN 3 will have severe dysplasia or carcinoma in situ ofthe penis [69].
In that penile cancer remains a rare disease in Western society, it can be assumed
that the progressive potential of these penile lesions must be low. When penile
squamous cancer does occur, however, over 50 percent oftumor biopsies contain HPV
16 or 18 [70].
Latent Genital HPVInfection Genital HPV infection is the most common viral
sexually transmitted disease. It isclear that assessments ofprevalence represent a gross
underestimate of exposed individuals. Filter hybridization of cervical smears has
detected latent HPV 16 infection in 17 percent of a random normal population [72]
and 29 percent of antenatal patients [73]. Forty-eight percent of women attending a
London sexually transmitted disease clinic were positive for HPV DNA despite having
negative cytology and colposcopy; 25 percent were positive for HPV 16 DNA
[Campion MJ: unpublished data]. A similarly large pool oflatent HPV infection exists
in the vaginal, vulvar, and penile epithelia.
The high prevalence of HPV types, including "high-risk" types, in clinically normal
women and men may argue against the virus being causally related to genital
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neoplasia. Alternately, when considered in view of the evidence implicating specific
HPVs in genital carcinogenesis, the high prevalence of latent infection may define a
very large at-risk group. It is clear that exposure to HPV alone may not be sufficient to
produce neoplastic transformation and malignancy. Observations in animal and
human models suggest a synergism between specific HPV infection and chemical or
physical carcinogens. Thus, a search for cofactors is critical to understanding the
significance of latent and subclinical HPV infection in relation to genital carcinogene-
sis.
HPV AND GENITAL CANCER: CASUAL OR CAUSAL ASSOCIATION
Specific HPV types are incriminated as the etiologic agent for a group of epithelial
proliferations which may progress to anogenital malignancy. The detection of HPV
DNA within genital tumor tissues must be distinguished from various statistical
associations between other sexually transmitted disease and cervical, vulvar, and penile
cancers. The relationship between HPV infection and malignancy is quite strict [58].
More than 90 percent of cancers contain oncogenic HPVs, and the same HPVs are
detected in malignancies throughout the world, despite the heterogeneity of the genus.
Archival cervical cancer specimens from the 1930s can also be shown to contain the
same HPV types [Collins J, McCance DJ: personal communication]. The cloning of
new papillomavirus types has increased the HPV DNA detection rate to 90 percent;
still fewer cancers will test negative as more probes become available.
The persistence of viral DNA in malignant cells has also been shown by the
detection of HPV DNA in cervical cancer-derived human cell lines. Seven of nine such
cell lines contain HPV DNA, including HeLa cells (derived from an HPV 18-
containing adenocarcinoma) and Ca-Ski cells (an HPV 16-containing squamous
carcinoma) [74].
The precursor lesions of anogenital malignancies frequently harbor the same
specific HPV types as those detected in the malignancy. In HPV 16- and HPV
18-associated neoplasia, there are alterations in physical state of the viral DNA within
the host cell between pre-malignant and malignant disease. Within pre-malignant
tissue, the viral DNA exists as a free episome (i.e., a self-replicating, extrachromo-
somal, nuclear plasmid). In contrast, most of the viral DNA within invasive cancers is
integrated into the host chromosomes (i.e., spliced into the host genome by covalent
bonds, often in tandem arrays) [74]. This condition occurs in particular with HPV 16-
and 18-containing tumors; however, some evidence suggests that HPV 10, HPV 11,
and HPV 33 may persist as an episome within cervical cancers, suggesting integration
may not always be a prerequisite for malignant transformation.
When viral integration occurs, in the several cases examined, integration occurred
near a cellular proto-oncogene (C-src, C-raf, C-myc) [75]. Furthermore, C-myc
and/or C-ha-ras oncogenes are amplified in a significant percentage of cervical
cancers, and C-myc mRNA levels are also elevated [75]. The integration exhibits an
interesting specificity with respect to the viral genetic regions. It is almost always at the
downstream (3') end of the El open reading frame (the main signal responsible for
maintaining viral DNA in an episomal state). Hence spatial disruption of this protein
coding area may favor viral integration and subsequent carcinogenesis [3 ]]. All cervical carcinoma cell lines analyzed to date, together with the majority of HPV
DNA-positive tumor biopsies tested, contain virus-specific transcripts for open reading
frames in the early region of the viral genome [40]. RNA mapping has revealed
320GENITAL HPV INFECTION
transcription of E6 or E6* (a message shortened by interval splicing). In addition, an
E7 protein has been identified in several cell lines. Preliminary experiments indicate
that continued expression of E6/E7 proteins may be required for maintenance of the
transformed state. The fact that transcription takes place in the genomically integrated
virus in squamous cell cancers and that a putative transforming segment, the E6, E7
open reading frame, is consistently transcribed argues strongly that the virus is playing
a role in the pathogenesis of human genital cancer and is consistent with the action of
other oncogenic viruses in other animal systems.
It appears highly probable that specific HPVs play an essential or pivotal role in the
etiology of anogenital cancer. It is not possible to decide whether these viruses are
necessary for tumor induction, maintenance, or both. As has been discussed, the
continued persistence of viral DNA and the fact that the viral DNA is actively
transcribed in pre-malignant and malignant cells are highly suggestive of a role in
maintenance of the malignant state. It is not possible, however, to exclude the
possibility that HPV may just be extremely efficient at persisting after initiation of
tumor progression. What is certain is that it is necessary to dispense with a unifactorial
theory for genital oncogenesis and consider the possible role of co-carcinogens in the
etiology of these cancers.
THE POSSIBLE OPERATION OF OTHER CO-CARCINOGENS
Given the probable role of papillomaviruses, it does seem unlikely that HPV
infection alone is sufficient to induce a carcinoma in an immunocompetent host. This
conclusion is suggested by the long lag time between initial infection and eventual
malignant conversion and by the spontaneous regression of many primary lesions. The
risk of a given viral type producing a carcinoma can be roughly estimated from the
ratio of the prevalence of that type in the normal population versus the prevalence of
HPV-positive cancers. Such a preliminary calculation indicates that only about one in
100 HPV 16-infected women will develop cervical cancer. The risk of malignant
progression of HPV 6, HPV11, or HPV 31 infections appears to be five- to tenfold
lower than for HPV 16. Deriving more reliable estimates of these risks will depend
upon prospective studies in HPV-infected women, matched for other risk factors.
Studies ofthe Shope papillomavirus system in rabbits have shown that carcinogene-
sis is influenced by the operation of additional etiologic agents [44,45]. Malignant
progression was facilitated by exposure to physical (ultraviolet light or X-rays) and
chemical carcinogens (dietary components, hydrocarbons). In addition, chronic irrita-
tion or inflammation exerted a weaker, less specific effect.
Plausible cofactors within the lower genital tract include tobacco products, infection
by other microbial agents, and immunosuppression. Heavy smoking has been impli-
cated as a risk factor, and tobacco metabolites have been detected in cervical mucus
[76], which permits a possible direct effect on the target cells within the transforma-
tion zone. Whether concomitant herpes virus infection could also act as a co-
carcinogen is an open question [77]. Nonetheless, it is conceivable that concomitant
herpetic infection might affect papillomavirus genes or cellular control genes, either of
which could change viral expression. An amplification of the C-myc or C-ras cellular
oncogenes or both has also been observed in the late stage ofcervical carcinomas. Such
an effect could also contribute to tumor progression.
Both the prevalence of genital condylomas and the risk of developing carcinoma in
situ are increased in immunosuppressed patients. The increased and accelerated
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progression of HPV-induced cervical atypia associated with impaired host immunity
contrasts with findings in the Shope papillomavirus, where corticosteroid administra-
tion did not influence malignant conversion ofpapillomas.
PROSPECTS FOR VACCINATION
If HPV infection is indeed necessary for the induction of anogenital cancer, the
prospect of controlling the disease by vaccination opens an exciting possibility. In
human medicine, healthy women cannot be deliberately infected with an oncogenic
papillomavirus. Hence, proof along the lines of experiments conducted in the Shope
papillomaviral system will never be possible. Rather, the best evidence ofcausality in
humans would be the demonstration that vaccination of non-exposed individuals
reduced the subsequent occurrence ofanogenital malignancy. Aside from the question
ofcancer prophylaxis, the morbidity resulting from condylomas and dysplasia, which
are clearly HPV-induced, may be reason enough for a vaccination program.
Observations in spontaneously regressing skin warts are most noteworthy. Histo-
logic examination reveals strong mononuclear cell infiltrates, and electron microscopy
has shown activated Langerhans cells and attacks by macrophages on HPV-infected
epidermal cells. These data indicate that wart cell-specific surface antigens are being
detected by the host's cell-mediated immune system. Once started, regression of
multiple warts is usually a systemic phenomenon, and the host thereafter remains
immune to reinfection by that HPV type.
Notwithstanding the host's potential to fight HPV infections, the immune response
is often weak and slow. This failure could reflect scant induction of HPV surface
antigens, perhaps in levels that are too low for immunologic detection. Hence,
vaccination might help to teach the immune system how to detect HPV-infected cells.
To this end, a vaccine would need to be based on specific virus-coded or virus-induced
membrane-bound proteins. Future research must therefore focus on the identification
and characterization ofsuch antigens. The Shope papillomavirus-rabbit model is then
probably the best system for evaluating the efficacy ofany vaccine designed to prevent
benign or malignant tumors, or both. In addition, vaccination might also offer the
prospect ofimmunotherapy for established disease.
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